Home
Screener
Insiders
Rankings
Sign in
Create account
Insiders
· Profile
Sullivan Christopher Ryan
Chief Financial Officer at Avalo Therapeutics. Filing since 10 Jun 2020.
CIK 0001810417
Company
Date
Role
Action
Shares
Amount
Of holding
AVTX
Avalo Therapeutics, Inc.
16 Sep 2026
Chief Financial Officer
Sold on a plan
12,394
$202.44K
23.7%
AVTX
Avalo Therapeutics, Inc.
10 Sep 2026
Chief Financial Officer
Sold on a plan
10,185
$179.46K
20.3%
AVTX
Avalo Therapeutics, Inc.
18 Aug 2026
Chief Financial Officer
Sold on a plan
31,031
$622.32K
43.7%
AVTX
Avalo Therapeutics, Inc.
17 Aug 2026
Chief Financial Officer
Sold on a plan
41,694
$828.10K
51.1%
AVTX
Avalo Therapeutics, Inc.
7 May 2026
Chief Financial Officer
Sold on a plan
18,606
$448.82K
97.8%
AVTX
Avalo Therapeutics, Inc.
6 May 2026
Chief Financial Officer
Sold on a plan
47,000
$948.72K
99.1%
AVTX
Avalo Therapeutics, Inc.
30 Apr 2026
Chief Financial Officer
Sold on a plan
8,457
$111.85K
95.2%
AVTX
Avalo Therapeutics, Inc.
29 Apr 2026
Chief Financial Officer
Sold on a plan
8,458
$110.74K
48.8%
AVTX
Avalo Therapeutics, Inc.
2 Apr 2026
Chief Financial Officer
Sold on a plan
7,980
$136.82K
31.5%
AVTX
Avalo Therapeutics, Inc.
1 Apr 2026
Chief Financial Officer
Sold on a plan
7,979
$133.77K
24.0%
AVTX
Avalo Therapeutics, Inc.
9 Jun 2023
Chief Financial Officer
Bought
511
$1.75K
68.0%
AVTX
Avalo Therapeutics, Inc.
10 Dec 2021
Chief Accounting Officer
Bought
955
$1.50K
11.9%
AVTX
Avalo Therapeutics, Inc.
10 Dec 2020
Interim CFO
Bought
5,095
$11.61K
172%
AVTX
Avalo Therapeutics, Inc.
10 Jun 2020
Interim CFO
Bought
2,954
$6.73K
opened
14 decisions on file.
